Table 2. . Dosing regimens.

Drug	Dose level	(Cycle 1 is 35 days; remainder are 28 days)
		Cycle 1	Cycle 2	Cycle 3+
Magrolimab	Starting dose	Priming dose: day 1 Maintenance dose: days 8, 15, 22, 29	Maintenance dose: days 1, 8, 15, 22	Maintenance dose: day 1, 15
Daratumumab†	16 mg/kg iv. or 1800 mg sc.	Days 8, 15, 22, 29	Days 1, 8, 15, 22	Days 1, 15 for cycles 3 to 6; day 1 of cycles 7+
Pomalidomide	4 mg p.o.	Days 1 to 21 daily	Days 1 to 21 daily	Days 1 to 21 daily
Carfilzomib‡	20/70 mg/m2 iv.	Days 8 (20 mg/m2), 15 (70 mg/m2), 22 (70 mg/m2)	Days 1, 8, 15	Days 1, 8, 15
Bortezomib	1.3 mg/m2 sc./iv.§	Days 8, 15, 22, 29	Days 1, 8, 15, 22	Days 1, 8, 15, 22¶
Dexamethasone	40 mg p.o.	Days 1, 8, 15, 22, 29#	Days 1, 8, 15, 22	Days 1, 8, 15, 22††

^†This arm will not receive treatment with dexamethasone.

^‡Recommended starting dose is 20 mg/m² on cycle 1, day 8. If tolerated, escalate dose to 70 mg/m² on cycle 1, day 15 and thereafter.

^§sc. is preferred over iv., where feasible.

^¶Maximum of 8 cycles in those who previously received bortezomib.

^#Administration on day 1 does not occur in the carfilzomib cohort.

^††Those patients in the magrolimab + carfilzomib + dexamethasone group will receive dexamethasone on days 1, 8, 15 and 22 from cycle 2 until cycle 9 and days 1, 8 and 15 from cycle 10 onward.

iv.: Intravenous; p.o.: Oral; sc.: Subcutaneous.